Although there are many drugs available to treat dermatological diseases, delivery of optimal doses for a number of disorders remains a challenge. Systemic administration of these drugs, through either oral ingestion or injection, requires extremely large doses, often accompanied by undesired toxicities or side effects. The obvious solution is to deliver the drug topically directly to the target tissue. Unfortunately, the barrier function of the skin restricts the quantity of drug delivered by conventional formulations. The small quantities of drug delivered limit the clinical efficacy of available topical formulations, resulting in frequent applications and long courses of treatment to provide only small, if any, clinical benefit.
Many approaches have been used to resolve these barriers to drug delivery. These include:
Iontophoresis, an electrochemical technology under development for nearly 20
years, has shown the most
promise, utilizing a low-voltage
direct electric current to induce fluid and particle
However, it is limited to a
small class of drugs which are
polarized and small enough to
permeated the skin.
MACROESISTM drug delivery utilizes electokinesis, a low-voltage electric current to induce fluid and particle movement. It involves the application of an electromotive force to transport ions and neutral molecules through a solid or liquid medium, in this case the protective stratum corneum, and into the epidermis. Ionized drugs (charged molecules) are transported actively by the force of the applied electrical field (electrorepulsion). Neutral, water soluble drug molecules are transported by electroosmosis, the bulk fluid flow associated with cation (positively charged molecules) transport by an electric field. Two electrodes are used in conjunction with the patientís skin to form a closed circuit, which allows the flow of current.
Our EUTIFORMTM technology uses a proprietary oral drug reformulation technology and has been shown to significantly improve solubility of active pharmaceutical ingredients by transforming physical structure without impacting chemical activity, thus maintaining their therapeutic effect. We have reformulated existing pharmaceuticals that have side effect challenges by creating a lower dose proprietary formulation. This would lower dosage required for immuno-suppressed individuals and offer new possibilities for viability of many existing drugs to new markets as well as new drugs under development. The initial reformulations will be licensed out to big Pharma and to generic drug companies.